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Genetic risk factors for major psychiatric disorders play key roles in neurodevelopment.
Thus, exploring the molecular pathways of risk genes is important not only for understand-
ing the molecular mechanisms underlying brain development, but also to decipher how
genetic disturbances affect brain maturation and functioning relevant to major mental ill-
nesses. During the last decade, there has been signiﬁcant progress in determining the
mechanisms whereby risk genes impact brain development. Nonetheless, given that the
majority of psychiatric disorders have etiological complexities encompassing multiple risk
genes and environmental factors, the biological mechanisms of these diseases remain
poorly understood. Howcanwemove forward to our research for discovery of the biological
markers and novel therapeutic targets for major mental disorders? Here we review recent
progress in the neurobiology of disrupted in schizophrenia 1 (DISC1), a major risk gene for
major mental disorders, with a particular focus on its roles in cerebral cortex development.
Convergent ﬁndings implicate DISC1 as part of a large, multi-step pathway implicated in
various cellular processes and signal transduction. We discuss links between the DISC1
pathway and environmental factors, such as immune/inﬂammatory responses, which may
suggest novel therapeutic targets. Existing treatments for major mental disorders are ham-
pered by a limited number of pharmacological targets. Consequently, elucidation of the
DISC1 pathway, and its association with neuropsychiatric disorders, may offer hope for
novel treatment interventions.
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INTRODUCTION
Disrupted in schizophrenia 1 (DISC1) was initially discovered at
the breakpoint in a balanced chromosomal translocation t (1; 11)
segregating with major mental conditions, such as schizophre-
nia, bipolar disorder, and major depression in a Scottish pedigree
(Millar et al., 2000). Since then, accumulating evidence from
genetic studies indicated that DISC1 is not only associated with
schizophrenia and mood disorders, but also other psychiatric dis-
orders of neurodevelopmental origin, such as autism, Asperger
syndrome, and agenesis of the corpus callosum (Hennah et al.,
2003; Hodgkinson et al., 2004; Callicott et al., 2005; Kilpinen et al.,
2008; Song et al., 2008, 2010; Osbun et al., 2011). Although recent
genome wide association studies (GWAS) have not found DISC1
as a key genetic risk factor for patients met the current diagnostic
criteria for schizophrenia (Purcell et al., 2009; Stefansson et al.,
2009; Mathieson et al., 2011), it is noted that variations of DISC1
inﬂuence anatomical and functional endophenotypes even in con-
trol subjects (Thomson et al., 2005; Di Giorgio et al., 2008; Prata
et al., 2008; Tomppo et al., 2009b). Collectively, genetic variation
of DISC1 may confer vulnerabilities to a wide range of neurode-
velopmental psychiatric conditions by affecting brain maturation,
thereby modifying brain function.
Consistently, extensive biological studies indicate that DISC1
plays a role in multiple cellular processes during and after brain
development (Chubb et al., 2008; Brandon and Sawa, 2011). In
fact, many protein binding partners of DISC1 are associated with
various molecular pathways that regulate fundamental cellular
processes for brain development and function (Table 1). Nonethe-
less, it is still unknown which functional aspects of DISC1 directly
affect molecular mechanisms underlying disease susceptibility.
How can we utilize accumulating biological data of DISC1 to dis-
cover novel therapeutic targets and biological markers for major
mental conditions? Here, we will review DISC1-associated mole-
cular pathways which have the potential to be novel therapeutic
targets,with particular focus onwell documentedDISC1 pathways
involved in cerebral cortex development and function (Figure 1).
Wewill also discuss the potential link of DISC1 pathways and envi-
ronmental factors, such as immune/inﬂammatory responses, to
explore therapeutic interventions based on understanding disease
mechanisms of genetic and environmental interaction.
DISC1 IN CEREBRAL CORTEX DEVELOPMENT
Disrupted in schizophrenia 1 plays a critical role for the regulation
of cell proliferation in thedeveloping cerebral cortex via the canon-
ical Wnt signaling pathway (Mao et al., 2009). The data suggested
that DISC1 inhibits the activity of glycogen synthase kinase 3
beta (GSK3β) via protein interaction, thereby stabilizing β-catenin
which is required for proper progenitor proliferation through
Wnt pathway. The same group later reported that DIX domain
containing-1 (DIXDC1), a homolog of the Wnt signaling genes
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Table 1 | DISC1 interacting proteins and functions.
DISC1 interactor Function Risk gene Reference
CENTROSOME/CYTOSKELETON
NDEL1 Neurite extension, migration + Morris et al. (2003), Ozeki et al. (2003), Kamiya et al. (2005),
Taya et al. (2007), Burdick et al. (2008)
NDE1 Proliferation + Burdick et al. (2008), Bradshaw et al. (2009)
PCM1 Microtubule organization + Kamiya et al. (2008)
BBS4 Migration, primary cilia function − Kamiya et al. (2008), Ishizuka et al. (2011)
KIF5A Neuronal transport − Taya et al. (2007)
14-3-3ε Migration axon growth + Taya et al. (2007)
FEZ1 Neurite extension + Miyoshi et al. (2003)
Kendrin Centrosome function − Miyoshi et al. (2004)
MAP1A Microtubule associated − Morris et al. (2003)
MIPT3 Microtubule associated − Morris et al. (2003)
SYNAPSE
Kalirin-7 Dendritic spine/synapse function − Hayashi-Takagi et al. (2010)
TNIK Dendritic spine/synapse function + Wang et al. (2011)
Citron Rho signaling, synapse function + Ozeki et al. (2003)
NUCLEUS
ATF4 Transcription factor − Morris et al. (2003), Sawamura et al. (2008)
N-CoR Corepressor for gene transcription − Sawamura et al. (2008)
OTHER
PDE4B cAMP signaling + Millar et al. (2005)
Girdin AKT signaling + Enomoto et al. (2009), Kim et al. (2009)
Grb2 Tyrosine kinase mediated signal transduction − Shinoda et al. (2007)
DBZ PACAP signaling − Hattori et al. (2007)
Mitoﬁlin Mitochondrial function − Park et al. (2010)
Many protein binding partners of DISC1 have been reported. DISC1 may function as an anchoring molecule to regulate various molecular pathways via interaction
with said protein interactors in a context dependent manner.
FIGURE 1 | Multiple roles for DISC1 in cerebral cortex in the
developmental trajectory. Various DISC1-mediated pathways with many
binding partners and environmental factors synergistically affect proper
cerebral cortex development and function. For reviews of the other DISC1
interactors, see Brandon and Sawa (2011), Porteous et al. (2011), Soares et al.
(2011).
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Disheveled axin, interacts with DISC1 to co-modulate GSK3β/β-
catenin signaling for proper cell proliferation (Singh et al., 2010).
Accumulating evidences have shown that GSK3β signaling may
be involved in various neuropsychiatric disorders, such as schizo-
phrenia, autism, and Alzheimer’s disease, suggesting that GSK3β
appears as a prominent therapeutic target for mental disorders
(Bachmann et al., 2005; Hur and Zhou, 2010). In fact, lithium,
the mood stabilizer which is commonly used for the treatment of
bipolar disorder, is known to inhibit GSK3 activity (Stambolic
et al., 1996). The other psychoactive drugs, such as clozapine,
risperidone, and valproic acid, have also been reported to affect
GSK3β activity (Stambolic et al., 1996; Kang et al., 2004; Li et al.,
2007; Rowe et al., 2007). Nonetheless, since GSK3β regulates var-
ious downstream effectors, which are not only implicated in the
Wnt pathway, but also other signaling required for cellular devel-
opment, such as sonic hedgehog and Notch signaling pathways
(Hur and Zhou, 2010), it is important to examine speciﬁc GSK3β-
mediated pathways relevant to disease mechanisms to ﬁnd novel
therapeutic strategies. In this regard, it may be ideal to focus
on DISC1-mediated GSK3β pathways, especially those in associa-
tion with other genetic risk factors, to explore disease-associated
molecular mechanisms. For instance, collapsin response media-
tor protein-2 (CRMP-2)/dihydropyrimidinase-like-2 (DPYSL2),
a susceptibility gene for schizophrenia (Nakata et al., 2003), is
reported to be a potential protein interactor of DISC1 by yeast-
two-hybrid screening (Camargo et al., 2007). Interestingly,CRMP-
2/DPYSL2 is known to be phosphorylated by GSK3β for the
regulation of axon outgrowth (Yoshimura et al., 2005).
Neuronal migration is a fundamental cellular process that is
required for proper cortical organization. Many groups have con-
sistently reported that knockdown of DISC1 using RNA interfer-
ence (RNAi) impaired radial neuronalmigration in the developing
cerebral cortex (Kamiya et al., 2005, 2008; Kubo et al., 2010; Singh
et al., 2010; Young-Pearse et al., 2010; Ishizuka et al., 2011). Find-
ings from these studies suggest that DISC1, along with many pro-
tein binding partners, regulate neuronalmigration via centrosome
and microtubule-dependent mechanisms. Of note, some of these
binding partners are known as risk or causative genes for vari-
ous neuropsychiatric disorders. These include nuclear distribution
element-like (NDEL1) and pericentriolar material 1 (PCM1), risk
genes for schizophrenia, and BBS4, a causative gene for Bardet–
Biedl syndrome that frequently accompanies impaired cognition,
mental retardation, and psychosis (Burdick et al., 2008; Kamiya
et al., 2008; Tomppo et al., 2009a). Amyloid precursor protein
(APP) also interacts with DISC1 to recruit DISC1 to the centro-
some for regulation of neuronal migration (Young-Pearse et al.,
2010). Furthermore, DISC1 is a component of the LIS1/dynein
motor complex (Kamiya et al., 2005). Mutations in human LIS1
gene cause classical lissencephaly resulting in mental retardation
(Pilz et al., 1998). Consistently, LIS1 heterozygous knockout mice
in which LIS1 expression is reduced, display disorganization of
proper cortical layer formation and behavioral abnormalities, such
as impaired spatial learning and motor function, indicating that
this is a good animal model for human lissencephaly caused by
LIS1 haploinsufﬁciency (Hirotsune et al., 1998). Interestingly, the
prenatal administration of ALLN, a calpain inhibitor which pre-
vents the degradation of LIS1, is effective to ameliorate neuronal
migration defect and improve motor coordination in this animal
model (Yamada et al., 2009).
Althoughmental disorders undoubtedly have genetic complex-
ities and could not be explained by the simple“haploinsufﬁciency”
model as the case of lissencephaly, elucidation of risk genes, and/or
molecules in their interactome, speciﬁcally ones with enzymatic
activity, may offer hope for novel treatment interventions for
neuropsychiatric disorders. In this regard, endo-oligopeptidase
activity of NDEL1 is quite interesting from a drug discovery view-
point (Hayashi et al., 2005). As a matter of fact, inhibitors of
angiotensin-converting enzyme (ACE), an exopeptidase, are cur-
rently being used to treat hypertension and renal disease (Izzo
and Weir, 2011), making peptidase activity an attractive drug tar-
get.Although endogenous substrates forNDEL1-oligopeptidase in
brain development remain unknown, in vitro experiments identi-
ﬁed several oligopeptides, such as neurotensin and bradykinin, as
potential targets for NDEL1 (Camargo et al., 1983). Interestingly,
neurotensin has a modulatory effect on neurotransmitter systems,
including dopaminergic neurons, which may be involved in the
pathophysiologies of schizophrenia (Boules et al., 2007).
Posttranslational modiﬁcations, which affect the functional
diversity of target proteins, could also have potential as novel drug
targets and biological markers in the DISC1 pathways. We have
recently reported that phosphorylation of DISC1 at Serine 710 is
a molecular switch signaling from cell proliferation to neuronal
migration in the developing cerebral cortex (Ishizuka et al., 2011).
By utilizing in utero electroporation, this study has shown that a
phosphor-dead mutant DISC1 can rescue only the proliferation
defect elicited by DISC1 knockdown, whereas a phosphor-mimic
mutant of DISC1 can exclusively recover impaired migration. The
question arises whether the phosphorylation of DISC1 at Serine
710 may be involved in the pathophysiologies of major mental
disorders, such as schizophrenia. It is obviously impractical to
investigate the phosphorylation status of DISC1 in the developing
human brain from subjects at risk of developing schizophrenia.
Nonetheless, recent progress in induced pluripotent stem (iPS)
cell technology will open new avenues to characterize such ﬁnd-
ings from preclinical studies using patient-derived neuronal cells,
which might in turn identify biological markers for major mental
disorders.
DISC1 AND GLUTAMATE SIGNALING FOR SYNAPTIC
FUNCTION
Disrupted in schizophrenia 1 impacts upon brain development
may be a challenge for treatment intervention. However, synap-
tic deﬁcits revealed by the DISC1 pathway offer some potential
for development of targeted pharmacologic intervention. Early
reports suggested a role for DISC1 in neurite outgrowth (Miyoshi
et al., 2003;Ozeki et al., 2003). Subsequent ﬁndings underline roles
for DISC1 in regulating dendritic spines of the glutamate synapse
(Hayashi-Takagi et al., 2010). Rac1 is activated by Karilin-7, lead-
ing to increased spine size following NMDA glutamate receptor
activation. However, DISC1 appears to interact with Karilin-7,
preventing access to and activation of Rac1 until NMDA recep-
tor activation promotes release of Kal-7 and spine enlargement.
Pharmacologic tools to modulate the Karilin-7/DISC1 interaction
might be a means to regulate spine maintenance.
www.frontiersin.org March 2012 | Volume 3 | Article 25 | 3
Kamiya et al. Potential therapeutic target in DISC1 pathway
TRAF2- and NCK-interacting kinase (TNIK) represents
another potential pharmacological target in the DISC1 protein
interaction network. TNIK is found in postsynaptic densities
and regulates c-Jun kinase, the actin cytoskeleton and a num-
ber of Wnt pathway effectors (Fu et al., 1999; Taira et al., 2004;
Mahmoudi et al., 2009). Genetic association studies have found
single-nucleotide polymorphisms of TNIK associated with schiz-
ophrenia (Potkin et al., 2009; Shi et al., 2009). TNIK mRNA
expression was increased in the dorsolateral prefrontal cortex of
schizophrenia subjects (Glatt et al., 2005) and in lymphoblasts
of monozygotic twins discordant for bipolar disorder (Matigian
et al., 2007). A yeast-two-hybrid screen using DISC1 as “bait”
identiﬁed TNIK as an interactor (Camargo et al., 2007). Subse-
quently, TNIK and DISC1 were shown to interact in mouse brain
(Wang et al., 2011). DISC1 was found to inhibit the kinase activity
of TNIK, an action that could be reproduced by a small pep-
tide derived from the DISC1 interaction site. This DISC1 peptide
led to increased actin polymerization and decreased expression
of a number of postsynaptic density proteins, including PSD95,
stargazin, AMPA receptor subunit GluR1 and TNIK, itself (Wang
et al., 2011).
DISC1 AND NEUROIMMUNE/INFLAMMATORY PROCESSES
Microbial infections have been recognized as environmental fac-
tors responsible for the increased incidence of schizophrenia and
associated disorders (Brown and Derkits, 2010; Sham et al., 1992;
Torrey and Yolken, 2003). These reports have been supported by
the epidemiological ﬁndings of an association between elevated
cytokines in maternal serum and schizophrenia in the offspring
(DeLisi andWyatt, 1982; Patterson, 2007; Miller et al., 2009). Sub-
sequently, it has been demonstrated that it is thematernal immune
response to a microbe that may contribute to the increased risk of
schizophrenia. The role of cytokines in innate immune response
makes them promising candidates for studying their functions in
disruption of fetal brain development in vulnerable individuals
(Dantzer et al., 2008). Most studies with prenatal immune activa-
tion have thus far used wild-type mice and rats. However, recently,
there have been several reports on developing and characterizing
animal models based on combining prenatal immune activation
with genetic mutations relevant to schizophrenia (Ibi et al., 2010;
Ehninger et al., 2012).
We have been studying possible roles for DISC1 in modula-
tion of poly I:C-induced immune activation in pregnant mice to
mimic prenatal in utero exposure to viruses as a model of gene–
environment interactions relevant to schizophrenia (Abazyan
et al., 2010). Our ﬁndings have suggested that DISC1 may be
involved in mediating neuroimmune interplay in this mouse
model. Given the extended interactome of DISC1, it is not sur-
prising that this protein is at the crossroads of the signaling
transduction pathways activated by immune factors.
One can envision multiple interactions between the path-
ways impacted by mutant DISC1 and activated by cytokines
and/or bacterial lipopolysaccharide (LPS) and poly I:C itself via
cytokine receptors or toll-like receptors (TLR) expressed by neu-
rons or glia cells, respectively. One of the major common path-
ways is the phosphoinositide-3 kinase/AKT-signaling network
(PI3K/AKT) that is activated by cytokines and poly IC and has
been demonstrated to interact with DISC1 partners (Camargo
et al., 2007). Another example is interactions with GSK3β, a key
regulator of the host inﬂammatory response and the production
of pro- and anti-inﬂammatory cytokines (Hayden et al., 2006). As
described above, DISC1 inhibits GSK3β activity through a direct
interaction (Mao et al., 2009). We also found altered poly I:C-
induced phosphorylation of GSK3β in mutant DISC1 newborn
mice that might at least in part explain altered basal and poly
I:C-induced production of cytokines in fetal brains and resultant
affective behaviors in adult offspring (Abazyan et al., 2010). These
observations are consistent with an emerging role for GSK3β in
inﬂammation-associated depression and anxiety (Jope, 2011).
Many immune effects of GSK3β are related to its regulation
of critical transcription factors, including nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB; Hayden et al.,
2006). A family of TLRs acts as primary sensors that detect a
wide variety of microbial components and elicit innate immune
responses. All TLR signaling pathways culminate in activation
of NF-κB, which controls the expression of an array of inﬂam-
matory cytokine genes. Stimulation with TLR ligands triggers
the rapid phosphorylation of speciﬁc serine residues of inhibitor
of κB (IκB) proteins by the IκB kinase (IKK) complex. Phos-
phorylated IκB proteins are subsequently polyubiquitinated and
degraded, allowingNF-κB tomove into the nucleus. This so-called
“canonical pathway” is involved in TLR-mediated induction of
inﬂammatory cytokines such as tumor necrosis factor-α (TNF-α)
and interleukin-6 (IL-6; Hayden et al., 2006). Prior studies with
DISC1 have demonstrated that DISC1, particularly a nuclear iso-
form of the protein, can play an important role in regulation of
transcription activity in the nucleus (Sawamura et al., 2008). Our
pilot in vitro experiments demonstrated that DISC1 may impact
NF-κB signaling. We found that expression of mutant DISC1
in N2 a neuronal cells led to delaying a recovery of IκBα after
TNF-α-inducedphosphorylation andubiquitinationof IκBα. This
prolonged degradation due to expression of mutant DISC1 seems
to suggest that perturbation in functions of DISC1 could also
affect (e.g., stimulate) pro-inﬂammatory signaling transduction
cascades in neurons.
In addition to immune signaling pathways,DISC1 and perhaps
other candidate genes can play a signiﬁcant role in the cellular
processes utilized by microbes during their life cycles (Carter,
2009). It has been proposed that the involvement of DISC1 in
the control of the microtubule network might be important both
in viral trafﬁc and in the rerouting of microtubules to the vacuoles
formed by T. gondii (Carter, 2009).
Recent clinical trials of anti-inﬂammatory add-on therapy
in schizophrenia have demonstrated superior beneﬁcial treat-
ment effects when antipsychotics were co-administered with
anti-inﬂammatory compounds, as compared with treatment out-
comes using antipsychotics alone (Meyer et al., 2011). How-
ever, a broad non-speciﬁc anti-inﬂammatory or immunosup-
pressive treatments that may have several unwanted effects such
as increased sensitivity to infections (Meyer et al., 2011). Ulti-
mately, future therapeutic approaches will result from deciphering
intracellular pathways that underlie convergence of environmen-
tal inﬂuences and genetic predisposition and their inﬂuence on
neurodevelopmental processes.
Frontiers in Psychiatry | Molecular Psychiatry March 2012 | Volume 3 | Article 25 | 4
Kamiya et al. Potential therapeutic target in DISC1 pathway
CONCLUSION REMARKS
Disrupted in schizophrenia 1-mediated pathways play multiple
roles for critical cellular processes through many protein bind-
ing partners in a context dependent manner. Nonetheless, it is
still unknown which functional aspect of DISC1 directly affects
molecular mechanisms underlying disease susceptibility. Are all
DISC1 functions in such cellular events implicated in disease
processes or are only some speciﬁc functional aspects critical?
This is a tremendously difﬁcult question, because the mole-
cular disposition of DISC1 is complex as reﬂected by multi-
ple isoforms at both mRNA and protein levels (Ishizuka et al.,
2006; Nakata et al., 2009). Nonetheless, biological functions of
DISC1 are currently being explored without waiting for the com-
plete identiﬁcation of DISC1 isoforms, resulting in the identi-
ﬁcation of multiple roles of DISC1 in various functional con-
texts. In fact, in addition to the roles in cerebral cortex we
reviewed here, DISC1 also contributes to brain development and
function in other brain regions, such as hippocampal regions
(Enomoto et al., 2009; Kim et al., 2009; Meyer and Morris, 2009).
Further investigations with advanced genetic engineering tech-
niques, which allow us to dissect region and cell type-speciﬁc
DISC1 functions in a temporal manner, might contribute to
more clearly elucidate DISC1 functions relevant to psychiatric
disorders.
As complete functional recovery is unlikely for neurodevelop-
mental disorders, such as schizophrenia, developing preventive
strategies is particularly important. Indeed, if the ﬁndings on
microbial etiologies and resultant immune dysfunction are repli-
cated, simple public health measures may prove beneﬁcial in
diminishing the incidence of infections during pregnancy to pre-
vent an appreciable proportion of schizophrenia cases. For exam-
ple, inﬂuenza vaccination, improved hygiene to prevent T. gondii
infection, and antibiotics to treat genital/reproductive infections
are feasible strategies already employed (BrownandDerkits,2010).
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